Peter F. Way, CFA
Contributor since: 2009
Company: Peter way associates
Articles
Market-Makers' ETF Intelligence: Friday, May 22, 2020
Everbridge: Now A Better Near-Term Investment Bet Than Microsoft
Karyopharm Therapeutics: Getting Paid Well For Accepting Uncertainty
Lumentum Now A Better Bet Than Tesla
ZROZ: The Fed Now Buys ETFs, You Might Too
Buy ManTech Again - With Last Month Buy's +12% Gain
How To Tell When Stock Prices   Are Too High - Or Too Low
Gilead Sciences: COVID-19 Effective Control Potential
Best Buy Of Upcoming-EPS-Report Stocks: Equifax
The Off-Balance Market
XSD The Best Industry-ETF To Buy For Cap Gain Now, Replace Soon
Buy ManTech International For Near Capital Gains During The Virus Pandemic
Paylocity: Best Internet Cloud-Based App Stock To Buy Now
Among Dow Jones Stocks, Pros Pick Microsoft Over Coca-Cola
Five9 Inc.: A Top Capital Gain Candidate
HubSpot, Inc.: A Top Near-Term Capital Gain Candidate
Ultra Clean Holdings, Inc.: A Top Near-Term Capital-Gain Candidate
Market Anxiety Pictured In Aggregate Fear-Greed Stock Measures
Best DJ Stocks For Near-Term Price Recovery
SPXL ETF: Best Current Near-Term Capital Gain Candidate
Securities Prices: The Balance Between Sellers And Buyers
Arrowhead Pharmaceuticals: Greed Vs. Fear
Ferrari Or Dorman: Better Auto Stock Bets Than Tesla
Eldorado Resorts: A Likely Near-Term Winner Among Its Gaming Peers
Varonis Systems, Inc.: An Appealing Profit-Gaining Opportunity
Align Technology: An Investing-Risk Learning, Profit-Gaining Opportunity
Sarepta Therapeutics, Inc. And Arrowhead Pharmaceuticals Now Top-Ranked Biotech Stock Buys
Arrowhead Pharmaceuticals, Inc.: A Better Odds-On Capital-Gain Alternative To Alkermes
Novanta, Inc.: A Better Odds-On Capital-Gain Alternative To Intuitive Surgical
PROS Holdings, Inc.: A Best-Valued Odds On Near-Term Capital Gainer
Veracyte, Inc.: An Undervalued Odds-On Near-Term Capital-Gainer
Chegg, Inc.: An Unrecognized Odds-On Near-Term Capital-Gainer